TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07871513: A Phase 2 Study to Evaluate the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA for the Treatment of Moderate to Severe Upper Facial Lines in Adults

Sponsor: AbbVie · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,772,800

Rescue Site Savings

+$4,482,000

Unlock Full NCT07871513 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07871513 Rescue Dossier →